Amgen, on the other hand, supports a GIP antagonist strategy and is developing AMG-133, a molecule that combines GLP-1 agonism with GIP antagonism, for obesity treatment (NCT04478708). The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.